BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32961371)

  • 1. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
    Lemieux C; Johnston LJ; Lowsky R; Muffly LS; Craig JK; Shiraz P; Rezvani A; Frank MJ; Weng WK; Meyer E; Shizuru J; Arai S; Negrin R; Miklos DB; Sidana S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):e328-e332. PubMed ID: 32961371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia.
    Martino R; Bellido M; Brunet S; Sureda A; Peyret M; Guárdia R; Altés A; Domingo-Albós A; Sierra J
    Bone Marrow Transplant; 1998 May; 21(10):1023-7. PubMed ID: 9632276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
    Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
    Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
    Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.
    Lawless S; Iacobelli S; Knelange NS; Chevallier P; Blaise D; Milpied N; Foà R; Cornelissen JJ; Lioure B; Benjamin R; Poiré X; Minnema MC; Collin M; Lenhoff S; Snowden JA; Santarone S; Wilson KMO; Trigo F; Dreger P; Böhmer LH; Putter H; Garderet L; Kröger N; Yaukoub-Agha I; Schönland S; Morris C
    Haematologica; 2023 Apr; 108(4):1105-1114. PubMed ID: 35770529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
    Willemze R; Labar B
    Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
    Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
    Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
    Rodríguez-Arbolí E; Martínez-Cuadrón D; Rodríguez-Veiga R; Carrillo-Cruz E; Gil-Cortés C; Serrano-López J; Bernal Del Castillo T; Martínez-Sánchez MDP; Rodríguez-Medina C; Vidriales B; Bergua JM; Benavente C; García-Boyero R; Herrera-Puente P; Algarra L; Sayas-Lloris MJ; Fernández R; Labrador J; Lavilla-Rubira E; Barrios-García M; Tormo M; Serrano-Maestro A; Sossa-Melo CL; García-Belmonte D; Vives S; Rodríguez-Gutiérrez JI; Albo-López C; Garrastazul-Sánchez MP; Colorado-Araujo M; Mariz J; Sanz MÁ; Pérez-Simón JA; Montesinos P;
    Transplant Cell Ther; 2021 Apr; 27(4):311.e1-311.e10. PubMed ID: 33836871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
    Knop S; Engelhardt M; Liebisch P; Meisner C; Holler E; Metzner B; Peest D; Kaufmann M; Bunjes D; Straka C; Fischer T; Sezer O; Hentrich M; Ostermann H; Bassermann F; Hess G; Hertenstein B; Freund M; Kropff M; Schmidt CA; Wolf HH; Jung W; Frickhofen N; Mielke S; Bargou RC; Maschmeyer G; Svaldi M; Langer CH; Gramatzki M; Hebart H; Kanz L; Einsele H;
    Leukemia; 2019 Nov; 33(11):2710-2719. PubMed ID: 31462732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
    Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
    Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
    Cwynarski K; van Biezen A; de Wreede L; Stilgenbauer S; Bunjes D; Metzner B; Koza V; Mohty M; Remes K; Russell N; Nagler A; Scholten M; de Witte T; Sureda A; Dreger P
    J Clin Oncol; 2012 Jun; 30(18):2211-7. PubMed ID: 22547610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
    Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
    Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.